To report 5 year efficacy and toxicity of intra-prostatic lesion boosting using standard and hypofractionated radiotherapy.

XXXXXXXXX (ISRCTNxxxxxxx) is a single centre phase II multi-cohort study including standardly fractionated (Cohort A: 74Gy/37F to prostate and seminal vesicles (psv); Cohort C 74 Gy/37F to psv plus 60 Gy/37F to pelvic lymph nodes) and moderately hypofractionated (Cohort B: 60Gy/20F to psv) prostate IMRT in patients with NCCN intermediate/high-risk disease.

Prostate cancer is the second most frequently diagnosed cancer among men worldwide, with the estimated sixth leading cause of cancer death. Despite major advancements in clinical biology and imaging, digital rectal examination (DRE), prostate-specific antigen (PSA), and biopsies indication remain the keystone for screening.

The aim of this study is to predict local failure after partial prostate re-irradiation for the treatment of isolated locally recurrent prostate cancer by using a machine learning classifier based on radiomic features from pre-treatment computed tomography (CT), positron-emission tomography (PET) and biological effective dose distribution (BED) of the radiotherapy plan.

To investigate the role of transrectal MRI fusion biopsy to select patients for prostate cancer focal therapy.

Patients with suspected prostate cancer underwent transrectal MRI fusion biopsy with the Koelis trinity device.

Based on in vitro studies, it is known that androgen deprivation therapy (ADT) increases prostate-specific membrane antigen (PSMA) expression on prostate cancer (PCa) cells. However, ADT also has cytoreductive effects which can decrease lesion size.

A significant number of men have persisting measurable prostate specific antigen (PSA) levels (>0.1ng/ml) after radical prostatectomy (RP), indicating a spectrum of prospect clinical courses of prostate cancer (PCa) after surgery; cancer in surgical site, understaged metastasis or circulating cancer cells.¹ As salvage radiotherapy (sRT) is an excellent local treatment option for the first possibility aforementioned, the others are needed systemic treatments. Thus, patient selection for proper treatment options in this heterogeneous group takes place with great importance.

We hypothesized that systematic biopsies (SBx) value for clinically significant PCa (csPCa) detection, in addition to mpMRI targeted biopsies (TBx), may vary significantly according to mpMRI index lesion (IL) characteristics.

Understanding the three-dimensional anatomy of percutaneous intervention in prostate cancer is essential to avoid complications. Recently, attempts have been made to use machine learning to automate the segmentation of functional structures such as the prostate gland, rectum, and bladder.

Results of three randomized clinical trials (RCTs) comparing adjuvant radiotherapy (ART) and early salvage radiotherapy (eSRT) of prostate carcinoma and a subsequent meta-analysis of the individual patient data from these RCTs were recently published.

To compare multiparametric magnetic resonance imaging (mpMRI) and transrectal ultrasound (TRUS) to estimate prostate volume and prostate specific antigen density (PSAD) as well as subsequent impact on prostate cancer (PCa) detection.